XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer

XtalPi joins hands with Of Singapore National Forum for Drug Discovery and Development to Find More Effective Treatment Options for Cancer Patients Worldwide

SHENZHEN CHINA And Singapore, December 19, 2022 / PRNewswire / – XtalPi, a Leading Artificial Intelligence (AI) and Automated Pharmaceutical Technology Company, today announced a strategic partnership with the Center for Experimental Pharmaceutical Development (EDDC). Of Singapore National Forum for Drug Detection and Development Organized by the Science, Technology and Research Agency of Singapore (A * STAR) to find new treatment candidates for non-small cell lung cancer (NSCLC).

Lung cancer is the second most common cancer and the leading cause of cancer death worldwide. NSCLC accounts for more than 80% of all lung cancer cases and its incidence continues to increase globally. Estimated global market size for NSCLC treatment will exceed $ 20 billion In 2027, according to research and marketing. Despite increased interest and investment in drug research, there is still a significant need for effective targeted treatment options for NSCLC patients to achieve optimal results.

Also Read :  Google On The Use Of AI Images

In this collaboration, XtalPi joins EDDC to implement its AI technology, automation platform, and expert domain knowledge to find potential candidates against NSDC-selected NSCLC targets. XtalPi will use its quantum physics and AI-driven platform to create and project through millions of molecules in De Novo Drug design. Highly effective molecules predicted with desirable drug properties will be validated and improved in its robotic synthesis and testing laboratories through Again. EDDC will provide insights and valuable data on novel NSCLC goals by speeding up the drug discovery process and accelerating the program towards development.

Also Read :  Biden Pardoned Weed Offenders. It Took Him a While to Get Here – Rolling Stone

Dr. SuhavenXtalPi Co-Founder and President commented, “We are pleased to establish this strategic partnership with EDDC. XtalPi is committed to serving patients worldwide by accelerating the scale, innovation and success rate of R&D drugs with AI and automation. Through this partnership, we look forward to continuing to expand our collaboration with top research institutes in the growing Pan-Asia biotechnology community, promoting rapid translation of new discoveries into clinical trials. Need more and contribute to improving the health and longevity of patients in Asia “And around the world.”

Professor Damian O’Connell“We are excited to partner with XtalPi in translating science and research into effective and targeted therapies for cancer treatment,” said EDDC CEO. AI Technology and Automation We are confident that this collaboration will accelerate the development of potential treatment options for the much-needed NSCLC patients.

Also Read :  Commerce lacks intelligence resources to keep U.S. tech from fueling Chinese cyberthreat, experts warn

About XtalPi

Founded in 2014, the founders of XtalPi recognize the common hurdles in the development of drugs related to solid polymers that can be successfully addressed with quantum physics predictions. Since then, XtalPi has maintained its focus on identification and then tapped out traditional barriers in biomedical R&D through innovative technologies. Through a substantial investment in automation and staffing, XtalPi now has four locations worldwide and employs approximately 1,000 people. XtalPi has been involved in research collaborations with the top 20 pharmaceutical companies in the world. Its ID4 platform combines physics-based simulation with experiments and automation upgrades for rapid synthesis and machine learning to increase prediction accuracy and subsequent processing efficiency.

Media Contact:
Roy Wang
[email protected]

Source: XtalPi Inc.


Leave a Reply

Your email address will not be published.